Incidence and Predictors of In-stent Restenosis Following Intervention for Pulmonary Vein Stenosis due to Fibrosing Mediastinitis

Abstract

Background Percutaneous transluminal pulmonary venoplasty (PTPV) is an emerging treatment for pulmonary vein stenosis (PVS) caused by fibrosing mediastinitis (FM). However, the incidence and predictors of in-stent restenosis (ISR) are elusive. We sought to identify the predictors of ISR in patients with PVS caused by extraluminal compression due to FM.

Methods We retrospectively enrolled patients with PVS-FM who underwent PTPV between July 1, 2018, and December 31, 2022. According to ISR status, patients were divided into two groups: the ISR group and the non-ISR group. Baseline characteristics (demographics and lesions) and procedure-related information were abstracted from patient records and analyzed. Univariate and multivariate analyses were performed to determine the predictors of ISR.

Results A total of 142 stents were implanted in 134 PVs of 65 patients with PVS-FM. Over a median follow-up of 6.6 (3.4-15.7) months, 61 of 134 PVs suffered from ISR. Multivariate analysis demonstrated a significantly lower risk of ISR in PVs with a larger reference vessel diameter (RVD) (odds ratio (OR): 0.79; 95% confidence interval [CI]: 0.64 to 0.98; P=0.032), and stenosis of the corresponding pulmonary artery (Cor-PA) independently increased the risk of restenosis (OR: 3.41; 95% CI: 1.31 to 8.86; P=0.012). The cumulative ISR was 6.3%, 21.4%, and 39.2% at the 3-, 6-, and 12-month follow-ups, respectively.

Conclusion ISR is very high in PVS-FM, which is independently associated with RVD and Cor-PA stenosis.

Central illustration

Based on the constructed prediction model, the RVD and stenosis of Cor-PA were found to be independently associated with ISR, and their sensitivity and optimal cutoff values for the prediction of restenosis are shown in (a) and (b), respectively. The risk of ISR significantly increased when PA stenosis occurred; the risk of restenosis decreased significantly when the RVD was larger than 8.4 mm.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2000033153

Funding Statement

This work was supported by the National Natural Science Foundation of China (82070052) and the Open Project of State Key Laboratory of Respiratory Disease (SKLRD-OP-202301).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ethics committee of Gansu Provincial Hospital reviewed and approved the study protocol (2022-302) on 25, August 2022 as well as granted exemption from obtaining informed consent from patients.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes